Type I Interferon in Chronic Virus Infection and Cancer

Trends in Immunology

Volumn 38, Issue 8, 2017, Pages 542-557

  Snell, Laura M ^a   McGaha, Tracy L ^a,b   Brooks, David G ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

cancer; CD4 T cell; CD8 T cell; chronic virus; dendritic cell; HCV; HIV; immune activation; immunotherapy; innate immunity; interferon alpha; interferon beta; LCMV; macrophage; persistent virus; T cell exhaustion; tumor; type I interferon

Indexed keywords

INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASM; REVIEW; VIRUS INFECTION; ANIMAL; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; INTERFERON TYPE I; NEOPLASMS; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 85019977333     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.05.005     Document Type: Review

References (135)

1. Gonzalez-Navajas, J.M., et al. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12 (2012), 125–135.
2. de Weerd, N.A., et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14 (2013), 901–907.
3. Klatt, N.R., et al. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol. Rev. 254 (2013), 326–342.
4. Bosinger, S.E., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 119 (2009), 3556–3572.
5. Harris, L.D., et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J. Virol. 84 (2010), 7886–7891.
6. Jacquelin, B., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119 (2009), 3544–3555.
7. Cunningham, C.R., et al. Type I and Type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. PLoS Pathog., 12, 2016, e1005356.
8. Mueller, S.N., et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 15430–15435.
9. Munn, D.H., Mellor, A.L., IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 37 (2016), 193–207.
10. Spranger, S., et al. Up-regulation of PD–L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med., 5, 2013, 200ra116.
11. Teijaro, J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340 (2013), 207–211.
12. Wilson, E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340 (2013), 202–207.
13. Benci, J.L., et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell, 167, 2016 1540–1554 e1512.
14. Dai, W., Gupta, S.L., Regulation of indoleamine 2, 3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J. Biol. Chem. 265 (1990), 19871–19877.
15. Jiang, G.M., et al. Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and indoleamine 2,3-dioxygenase downregulation. Cancer Immunol. Res. 5 (2017), 42–51.
16. McGaha, T.L., et al. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol. Rev. 249 (2012), 135–157.
17. Terawaki, S., et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186 (2011), 2772–2779.
18. Gajewski, T.F., et al. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
19. Ng, C.T., et al. Alpha and beta type 1 interferon signaling: passage for diverse biologic outcomes. Cell 164 (2016), 349–352.
20. Fenton-May, A.E., et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology, 10, 2013, 146.
21. Foster, T.L., et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 20 (2016), 429–442.
22. Parrish, N.F., et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6626–6633.
23. Sunshine, J.E., et al. Fitness-balanced escape determines resolution of dynamic founder virus escape processes in HIV-1 infection. J. Virol. 89 (2015), 10303–10318.
24. Song, H., et al. Transmission of multiple HIV-1 subtype C transmitted/founder viruses into the same recipients was not determined by modest phenotypic differences. Sci. Rep., 6, 2016, 38130.
25. Sherwin, S.A., et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248 (1982), 2461–2466.
26. Hall, M., et al. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11 (1995), 1581–1588.
27. Sangfelt, O., et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18 (1999), 2798–2810.
28. Bernardo, A.R., et al. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis., 4, 2013, e479.
29. Chawla-Sarkar, M., et al. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 7 (2001), 1821–1831.
30. Apelbaum, A., et al. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol. Cell Biol. 33 (2013), 800–814.
31. Bidwell, B.N., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18 (2012), 1224–1231.
32. Widschwendter, A., et al. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res. 8 (2002), 3065–3074.
33. Sandler, N.G., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511 (2014), 601–605.
34. Wonderlich, E.R., Barratt-Boyes, S.M., SIV infection of rhesus macaques differentially impacts mononuclear phagocyte responses to virus-derived TLR agonists. J. Med. Primatol. 42 (2013), 247–253.
35. Zuniga, E.I., et al. Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. Cell Host Microbe 4 (2008), 374–386.
36. Lee, M.S., et al. Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8(+) T-cell exhaustion. PLoS Pathog., 9, 2013, e1003478.
37. Wang, Y., et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11 (2012), 631–642.
38. Honke, N., et al. Immunoactivation induced by chronic viral infection inhibits viral replication and drives immunosuppression through sustained IFN-I responses. Eur. J. Immunol. 46 (2016), 372–380.
39. Nice, T.J., et al. Type I interferon receptor deficiency in dendritic cells facilitates systemic murine norovirus persistence despite enhanced adaptive immunity. PLoS Pathog., 12, 2016, e1005684.
40. Wilson, E.B., et al. Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection. Cell Host Microbe 11 (2012), 481–491.
41. Ohyagi, H., et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 39 (2013), 584–598.
42. Diamond, M.S., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
43. Fuertes, M.B., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
44. Treilleux, I., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10 (2004), 7466–7474.
45. Vermi, W., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200 (2003), 255–268.
46. Sisirak, V., et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 72 (2012), 5188–5197.
47. Munn, D.H., et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114 (2004), 280–290.
48. Mansfield, A.S., et al. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 9, 2009, 231.
49. Speeckaert, R., et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur. J. Cancer 48 (2012), 2004–2011.
50. Yamada, T., et al. Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated antiviral innate defense. Nat. Immunol. 17 (2016), 687–694.
51. Sharma, M.D., et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci. Adv., 1, 2015, e1500845.
52. Getts, D.R., et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 187 (2011), 2405–2417.
53. Ravishankar, B., et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3909–3914.
54. Huang, L., et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol. 191 (2013), 3509–3513.
55. Deng, L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852.
56. Woo, S.R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
57. Corrales, L., et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11 (2015), 1018–1030.
58. Luo, M., et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol., 2017, 10.1038/nnano.2017.52 Published online April 24, 2017.
59. Smith, T.T., et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J. Clin. Invest., 2017, 10.1172/JCI87624 Published online April 24, 2017.
60. Crouse, J., et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 40 (2014), 961–973.
61. Kolumam, G.A., et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202 (2005), 637–650.
62. Wiesel, M., et al. Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. Eur. J. Immunol. 42 (2012), 320–329.
63. Xu, H.C., et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 40 (2014), 949–960.
64. Thompson, L.J., et al. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J. Immunol. 177 (2006), 1746–1754.
65. Moseman, E.A., et al. Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation. Sci. Immunol., 1, 2016, eaah3565.
66. Hervas-Stubbs, S., et al. Effects of IFN-alpha as a signal-3 cytokine on human naive and antigen-experienced CD8(+) T cells. Eur. J. Immunol. 40 (2010), 3389–3402.
67. Katlinski, K.V., et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31 (2017), 194–207.
68. Wu, T., et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol., 1, 2016, eaai8593.
69. He, R., et al. Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. Nature 537 (2016), 412–428.
70. Im, S.J., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
71. Utzschneider, D.T., et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 45 (2016), 415–427.
72. Osokine, I., et al. Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 7409–7414.
73. Ray, J.P., et al. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity 40 (2014), 367–377.
74. Snell, L.M., et al. Overcoming CD4 Th1 cell fate restrictions to sustain antiviral CD8 T cells and control persistent virus infection. Cell Rep. 16 (2016), 3286–3296.
75. Feng, J., et al. Patients with chronic hepatitis C express a high percentage of CD4(+)CXCR5(+) T follicular helper cells. J. Gastroenterol. 47 (2012), 1048–1056.
76. Lindqvist, M., et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122 (2012), 3271–3280.
77. Petrovas, C., et al. CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Invest. 122 (2012), 3281–3294.
78. Ilander, M., et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS One, 9, 2014, e87794.
79. Ding, Z.C., et al. Polyfunctional CD4(+) T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 120 (2012), 2229–2239.
80. Ding, Z.C., et al. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 115 (2010), 2397–2406.
81. Ding, Z.C., et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res. 74 (2014), 3441–3453.
82. Srivastava, S., et al. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211 (2014), 961–974.
83. Che, J.W., et al. Regulatory T cells resist virus infection-induced apoptosis. J. Virol. 89 (2015), 2112–2120.
84. Veiga-Parga, T., et al. Role of regulatory T cells during virus infection. Immunol. Rev. 255 (2013), 182–196.
85. Penaloza-MacMaster, P., et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J. Exp. Med. 211 (2014), 1905–1918.
86. Yu, Y., et al. INFalpha–2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts. BMC Cancer, 16, 2016, 397.
87. Hashimoto, H., et al. Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther. 21 (2014), 532–541.
88. Bacher, N., et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res. 73 (2013), 5647–5656.
89. Stewart, C.A., et al. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J. Clin. Invest. 123 (2013), 4859–4874.
90. Sharma, M.D., et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 33 (2010), 942–954.
91. Boasso, A., et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109 (2007), 3351–3359.
92. Fahey, L.M., et al. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208 (2011), 987–999.
93. Noto, A., Pantaleo, G., B-cell abnormalities and impact on antibody response in HIV infection. Curr. Opin. HIV AIDS, 2017, 10.1097/COH.0000000000000359 Published online February 15, 2017.
94. Purtha, W.E., et al. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J. Virol. 82 (2008), 10964–10974.
95. Wieland, A., et al. Antibody effector functions mediated by Fcgamma-receptors are compromised during persistent viral infection. Immunity 42 (2015), 367–378.
96. Yamada, D.H., et al. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 42 (2015), 379–390.
97. Fallet, B., et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci. Immunol., 1, 2016, eaah6817.
98. Sammicheli, S., et al. Inflammatory monocytes hinder antiviral B cell responses. Sci. Immunol., 1, 2016, eaah6789.
99. Bergthaler, A., et al. Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol., 7, 2009, e1000080.
100. Velu, V., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458 (2009), 206–210.
101. Bindea, G., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
102. Nielsen, J.S., Nelson, B.H., Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology 1 (2012), 1623–1625.
103. Buisseret, L., et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/PD–L1 expression are linked in breast cancer. Oncoimmunology, 6, 2017, e1257452.
104. Castino, G.F., et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology, 5, 2016, e1085147.
105. Kroeger, D.R., et al. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22 (2016), 3005–3015.
106. Shinde, R., et al. B cell-intrinsic IDO1 regulates humoral immunity to T cell-independent antigens. J. Immunol. 195 (2015), 2374–2382.
107. Rosser, E.C., Mauri, C., Regulatory B cells: origin, phenotype, and function. Immunity 42 (2015), 607–612.
108. Bosinger, S.E., Utay, N.S., Type I interferon: understanding its role in HIV pathogenesis and therapy. Curr. HIV/AIDS Rep. 12 (2015), 41–53.
109. Azzoni, L., et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J. Infect. Dis. 207 (2013), 213–222.
110. Zitvogel, L., et al. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.
111. Heim, M.H., 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 13 (2013), 535–542.
112. Chen, L., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005), 1437–1444.
113. Sarasin-Filipowicz, M., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 7034–7039.
114. Guilhot, F., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N. Engl. J. Med. 337 (1997), 223–229.
115. Mandelli, F., et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 322 (1990), 1430–1434.
116. Osterborg, A., et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 81 (1993), 1428–1434.
117. Gogas, H., et al. Who benefits most from adjuvant interferon treatment for melanoma?. Am. J. Ther. 22 (2015), 54–60.
118. Alberts, D.S., et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol. Oncol. 100 (2006), 133–138.
119. Alberts, D.S., et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol. Oncol. 109 (2008), 174–181.
120. Hall, G.D., et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br. J. Cancer 91 (2004), 621–626.
121. Muss, H.B., et al. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J. Clin. Oncol. 2 (1984), 1012–1016.
122. Nethersell, A., et al. Recombinant interferon in advanced breast cancer. Br. J. Cancer 49 (1984), 615–620.
123. Sherwin, S.A., et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. J. Am. Med. Assoc. 248 (1982), 2461–2466.
124. Bell, J., McFadden, G., Viruses for tumor therapy. Cell Host Microbe 15 (2014), 260–265.
125. Roulois, D., et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162 (2015), 961–973.
126. Ruffell, B., et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (2014), 623–637.
127. Wilson, E.B., Brooks, D.G., The role of IL-10 in regulating immunity to persistent viral infections. Curr. Top. Microbiol. Immunol. 350 (2011), 39–65.
128. Mumm, J.B., et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 20 (2011), 781–796.
129. Vicari, A.P., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196 (2002), 541–549.
130. Chan, I.H., et al. PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO. Oncoimmunology, 5, 2016, e1197458.
131. Levin, D., et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal., 7, 2014, ra50.
132. Zhen, A., et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J. Clin. Invest. 127 (2017), 260–268.
133. Cheng, L., et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J. Clin. Invest. 127 (2017), 269–279.
134. Yang, X., et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25 (2014), 37–48.
135. Zaretsky, J.M., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.